多奈单抗和淀粉样蛋白β疗法在早期阿尔茨海默病中的前瞻性作用:系统综述

R. Chakraverty, Jyotirmoy Bondyopadhyay, Tatini Debnath
{"title":"多奈单抗和淀粉样蛋白β疗法在早期阿尔茨海默病中的前瞻性作用:系统综述","authors":"R. Chakraverty, Jyotirmoy Bondyopadhyay, Tatini Debnath","doi":"10.18231/j.ijpca.2024.004","DOIUrl":null,"url":null,"abstract":"Amyloid-β (Aβ) peptide accumulation in the brain, leading to amyloid plaques, is considered to be the starting point of Alzheimer's disease. It is believed that these plaques impair cognitive and functional capacities and induce neurodegeneration. Research on uncommon genetic variants that either increase or decrease the quantity of Aβ deposited offers proof that amyloid plaques are involved in the disease's progression. Early-stage amyloid plaque buildup increases the likelihood that moderate cognitive impairment may progress to dementia.Donanemab, a humanized IgG1 antibody, targets an N-terminal pyroglutamate Aβ epitope that is unique to plaques that have already begun to develop. It is specific to this epitope and has no known clinical effect. Furthermore, it doesn't show any off-target binding to neurotransmitters, their receptors, or other Aβ species. In this systematic review, we first collect the necessary information after carefully reviewing four different study articles. After the data is collected, we evaluate it and create a graph to compare those study articles.","PeriodicalId":14182,"journal":{"name":"International Journal of Pharmaceutical Chemistry and Analysis","volume":" 43","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prospective role of Donanemab and amyloid beta therapies in early Alzheimer’s disease: A systematic review\",\"authors\":\"R. Chakraverty, Jyotirmoy Bondyopadhyay, Tatini Debnath\",\"doi\":\"10.18231/j.ijpca.2024.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Amyloid-β (Aβ) peptide accumulation in the brain, leading to amyloid plaques, is considered to be the starting point of Alzheimer's disease. It is believed that these plaques impair cognitive and functional capacities and induce neurodegeneration. Research on uncommon genetic variants that either increase or decrease the quantity of Aβ deposited offers proof that amyloid plaques are involved in the disease's progression. Early-stage amyloid plaque buildup increases the likelihood that moderate cognitive impairment may progress to dementia.Donanemab, a humanized IgG1 antibody, targets an N-terminal pyroglutamate Aβ epitope that is unique to plaques that have already begun to develop. It is specific to this epitope and has no known clinical effect. Furthermore, it doesn't show any off-target binding to neurotransmitters, their receptors, or other Aβ species. In this systematic review, we first collect the necessary information after carefully reviewing four different study articles. After the data is collected, we evaluate it and create a graph to compare those study articles.\",\"PeriodicalId\":14182,\"journal\":{\"name\":\"International Journal of Pharmaceutical Chemistry and Analysis\",\"volume\":\" 43\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Pharmaceutical Chemistry and Analysis\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18231/j.ijpca.2024.004\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Pharmaceutical Chemistry and Analysis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18231/j.ijpca.2024.004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

淀粉样蛋白-β(Aβ)肽在大脑中积聚形成淀粉样蛋白斑块,被认为是阿尔茨海默病的起始点。据认为,这些斑块会损害认知和功能能力,诱发神经变性。对增加或减少 Aβ 沉积量的不常见基因变异的研究证明,淀粉样蛋白斑块与疾病的进展有关。早期淀粉样蛋白斑块的堆积会增加中度认知障碍发展为痴呆症的可能性。Donanemab是一种人源化IgG1抗体,它的靶点是N端焦谷氨酸Aβ表位,这是已经开始形成的斑块所独有的。该抗体对这一表位具有特异性,而且没有已知的临床效果。此外,它不会与神经递质、其受体或其他 Aβ 物种发生任何脱靶结合。在这篇系统性综述中,我们首先仔细查阅了四篇不同的研究文章,收集了必要的信息。收集数据后,我们对其进行评估,并绘制图表对这些研究文章进行比较。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Prospective role of Donanemab and amyloid beta therapies in early Alzheimer’s disease: A systematic review
Amyloid-β (Aβ) peptide accumulation in the brain, leading to amyloid plaques, is considered to be the starting point of Alzheimer's disease. It is believed that these plaques impair cognitive and functional capacities and induce neurodegeneration. Research on uncommon genetic variants that either increase or decrease the quantity of Aβ deposited offers proof that amyloid plaques are involved in the disease's progression. Early-stage amyloid plaque buildup increases the likelihood that moderate cognitive impairment may progress to dementia.Donanemab, a humanized IgG1 antibody, targets an N-terminal pyroglutamate Aβ epitope that is unique to plaques that have already begun to develop. It is specific to this epitope and has no known clinical effect. Furthermore, it doesn't show any off-target binding to neurotransmitters, their receptors, or other Aβ species. In this systematic review, we first collect the necessary information after carefully reviewing four different study articles. After the data is collected, we evaluate it and create a graph to compare those study articles.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信